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Abstract: Dogs provide highly valuable models of human disease due to the similarity in phenotype
presentation and the ease of genetic analysis. Seven Saluki puppies were investigated for neurological
abnormalities including seizures and altered behavior. Magnetic resonance imaging showed a
diffuse, marked reduction in cerebral cortical thickness, and symmetrical T2 hyperintensity in
specific brain regions. Cerebral cortical atrophy with vacuolation (status spongiosus) was noted on
necropsy. Genome-wide association study of 7 affected and 28 normal Salukis revealed a genome-
wide significantly associated region on CFA 35. Whole-genome sequencing of three confirmed
cases from three different litters revealed a homozygous missense variant within the aldehyde
dehydrogenase 5 family member A1 (ALDH5A1) gene (XM_014110599.2: c.866G>A; XP_013966074.2:
p.(Gly288Asp). ALDH5A1 encodes a succinic semialdehyde dehydrogenase (SSADH) enzyme critical
in the gamma-aminobutyric acid neurotransmitter (GABA) metabolic pathway. Metabolic screening
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of affected dogs showed markedly elevated gamma-hydroxybutyric acid in serum, cerebrospinal fluid
(CSF) and brain, and elevated succinate semialdehyde in urine, CSF and brain. SSADH activity in the
brain of affected dogs was low. Affected Saluki dogs had striking similarities to SSADH deficiency in
humans although hydroxybutyric aciduria was absent in affected dogs. ALDH5A1-related SSADH
deficiency in Salukis provides a unique translational large animal model for the development of novel
therapeutic strategies.
Keywords: inborn error of metabolism; encephalopathy; SSADHD; ALDH5A1; GABA;
4-hydroxybutyric acid; succinic semialdehyde; encephalopathy; whole-genome sequencing; precision
medicine; GWAS; inherited
1. Introduction
Inborn errors of metabolism (IEMs) are a group of diseases caused by an enzymatic deficiency
in a metabolic pathway, most commonly caused by a genetic mutation. While individually these
diseases are rare, as a group they are relatively common, with more than 500 IEM diseases reported in
people [1]; in animals, they are becoming increasingly recognized [2–6]. In diseases caused by an IEM,
clinical signs are due to the reduced or lack of production of a biochemical product, or accumulation of
an abnormal amount of substrate or substrates produced by alternative metabolic pathways, secondary
to the enzymatic deficiency. The diagnosis of an IEM may be a challenging, as clinical signs can be
vague and non-specific, and targeted diagnostic testing is required [7]. IEMs are often recognized in
young people and animals, and many have neurological manifestations [8,9].
Seizures are a common neurological sign in dogs [10]. Disorders causing seizures arise either
extracranially (reactive seizures), or intracranially [11] Epilepsy is a brain disease characterized by
a lasting predisposition to generate seizures, which is classified in dogs as structural epilepsy or
idiopathic epilepsy (OMIA 000344-9615) [11]. Causes of structural epilepsy include inflammation
(e.g., granulomatous meningoencephalitis), neoplasia, nutritional alterations (e.g., thiamine deficiency),
infection, anomalous entities (e.g., hydrocephalus), inborn errors of metabolism and trauma [11].
Dogs with idiopathic epilepsy (IE) are typically 6 months to 6 years of age and usually have normal
physical and neurological examinations between seizures [12]. Dogs younger than 6 months or older than
6 years of age usually have reactive seizures or structural epilepsy, rather than idiopathic epilepsy [12].
A seizure disorder reported in Salukis is called central nervous system status spongiosus in
Saluki dogs (SSSD). There are only brief reports of this disease in the literature [13,14]. One affected
8-month-old male puppy from a litter of 9 was reported with a 5 month history of seizures and
behavioral changes. The sire and dam were full siblings. All nine puppies and the sire were euthanized;
pathological changes were noted in the affected puppy and in two clinically normal littermates,
and the rest of the puppies and the sire were pathologically normal. Pathological changes in the
clinically affected puppy included widespread bilaterally symmetrical status spongiosis of the cerebrum,
brainstem and cerebellum at the grey–white matter junction, which extended into both the grey and
white matter. There were also lesions in the thalamus, optic nerve and internal capsule but no lesions
were noted in the spinal cord [13].
Recognized causes of early-onset symmetrical brain lesions include metabolic, nutritional and
toxin-induced diseases [15]. In Saluki dogs with SSSD, the clinical signs and lesions on MRI and
pathology appear to be breed specific, identical in distribution and type, and diagnosed in multiple
dogs over a long period of time (1987 [13] to 2020). Clinical signs developed while puppies were still
with the breeders, making toxicity a less likely cause; pathology differed from previously reported
nutritional [16] or toxic [17–19] central nervous system problems, and thus a genetic cause was
considered most likely. Although a metabolic disorder was not identified by routine diagnostic testing
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in affected Salukis, an underlying genetic abnormality causing a metabolic problem was most likely
based on the age of onset of clinical signs.
The purpose of this study was to define the phenotype of Salukis with SSSD and to determine
the underlying genetic cause in this breed. Comprehensive evaluations including MRI and necropsy,
as well as metabolic and enzyme activity testing, were performed on urine, serum, cerebrospinal fluid
and brain tissue from four affected puppies from two litters from the USA and a litter with three
affected puppies from Germany. All seven affected dogs were used for a genome-wide association
study (GWAS) followed by whole-genome sequence analysis of three affected puppies, which identified
a private homozygous missense variant in the canine ALDH5A1 gene.
2. Materials and Methods
2.1. Affected Dogs
From 2005 to 2015, seven Saluki dogs affected with SSSD from the USA (4) and Germany (3)
had DNA collected. Four dogs were examined—three dogs at the William R. Pritchard Veterinary
Medical Teaching Hospital at the University of California Davis (UCD) and one dog was evaluated at
Fachtierarzt fur Kleintiere, in Wiesbaden, Germany. All 4 dogs were presented by their breeders for
examination. A fifth Saluki dog affected with SSSD from the USA had a necropsy completed at UCD
Two additional German dogs were not evaluated clinically beyond the breeder’s description of the
clinical signs.
2.2. Control Dogs
2.2.1. MRI Evaluation
Four unaffected Saluki dogs related to the affected USA Saluki dogs were examined and had
magnetic resonance imaging of their brain and completed at Advanced Veterinary Medicine Imaging
in Los Angeles, California.
2.2.2. Targeted Metabolic Testing
Archived urine = 4, serum = 4, cerebrospinal fluid (3) and brain tissue (4) from 15 different
non-Saluki dogs unaffected by SSSD were utilized as control samples.
2.3. Affected Saluki Dogs
Blood work (complete blood count, and serum biochemical profile) was performed by the referring
veterinarians in two dogs (dogs 3 and 4). Cerebrospinal fluid sample (CSF) was collected in two
dogs (dogs 1 and 5). One CSF sample was routinely analyzed in Germany and the other sample
was collected at UCD and frozen at −80 degrees for further analysis. Two dogs had quantitative
urine organic acid testing completed at the University of California San Diego Biochemical Genetics
Laboratory (dogs 1 and 2). Urine was shipped to the lab by the breeder and was analyzed by the
lab 18 days later. Four dogs had complete necropsies completed at UCD, and one had a necropsy at
Ludwig Maximilians Universität München in Germany. The owners consented to the necropsy and
processing of postmortem samples. Following necropsy, the brain was immediately immersed in 10%
neutral buffered formalin followed by standard paraffin embedding. Selected regions were sectioned
at 5 µm slice thickness and stained with hematoxylin-eosin and luxol fast blue-cresyl violet.
MRI and Histopathology
Six Saluki dogs underwent MRI of the brain—two affected Saluki dogs underwent magnetic
resonance imaging (MRI) of the brain at UC Davis, and four unaffected Saluki dogs had imaging of the
brain at Advanced Veterinary Medicine Imaging in Los Angeles, California. Both locations used a
1.5 T MRI system (GE Signa, GE Healthcare, Waukesha, WI, USA), with paired 5” general purpose
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radiofrequency coils. Sagittal T1-weighted (T1W) and T2-weighted (T2W) images, transverse T1W,
T2W, fluid attenuating inversion recovery (FLAIR), and T2*-weighted (T2*W) images, and dorsal T2W
images were acquired of the brain. Sagittal, transverse, and dorsal T1W images were repeated after
intravenous administration of 0.1 mmol/kg gadopentetate dimeglumine (Magnevist, Bayer, Whippany,
NJ, USA).
2.4. Sample Collection and DNA Extraction
Blood samples, pedigree, and phenotype information were collected from 7 affected dogs and
18 close relatives of affected dogs including 4 parents (Figure 1). Additional samples were collected
from 48 healthy Saluki dogs. Healthy dogs of other breeds (n = 228) were used that were part of a
DNA repository at UC Davis. DNA was extracted from EDTA whole blood samples using Gentra
Puregene DNA purification extraction kit (Qiagen, Valencia, CA, USA). Collection of canine samples
was approved by the University of California, Davis Animal Care and Use Committee (protocol #18561)
and the Cantonal Committee for Animal Experiments (Canton of Bern; permit 75/16).
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Figure 1. Pedigree of seven succinic semialdehyde dehydrogenase deficiency (SSADHD)-affected 
Saluki dogs. Females are depicted by circles and males by squares. Black fill indicates affected 
puppies. Numbers indicate 25 dogs from which samples were available. The blue contour indicates 
animals that were genotyped on SNP array, and the red contour the three affected dogs selected for 
the WGS. Note that the two litters on the left were seen in the USA and the third litter on the right in 
Germany. A common male ancestor illustrates the genealogical relatedness. 
2.5. Genome-Wide Association Scan 
SNP genotyping was performed using the Illumina Canine HD 174,000 SNP array (Illumina, San 
Diego, CA, USA) for 7 affected cases and 28 neurologically normal adult Saluki controls. Genome-
wide association analysis was performed using Plink [20]. SNPs were pruned from analysis if the 
minor allele frequency was <5% and the call rate <90%. Chi-square association analysis, Bonferroni 
adjustments, and genomic inflation calculations were performed in Plink. Figure 5 was made in R 
using ggplot2 [21,22]. 
2.6. Whole-Genome Sequence  
Whole-genome sequencing (WGS) was performed on the two affected Salukis from the USA and 
compared to 98 controls dogs from various breeds as reported, and coverage was 6.4× for 1052 and 
5.3× for 5813 SRA: SRR5311685 and SRR5311664 (study: PRJNA377155) [23]. Segregation of variants 
was performed using 2 cases compared to 98 controls within the homozygous interval identified by 
Figure 1. Pedigree of seven succinic semialdehyde dehydrogenase deficiency (SSADHD)-affected
Saluki dogs. Females are depicted by circles and males by squares. Black fill indicates affected puppies.
Numbers indicate 25 dogs from which samples were available. The blue contour indicates animals
that were genotyped on SNP array, and the red contour the three affected dogs selected for the WGS.
Note that the two litters on the left were seen in the USA and the third litter on the right in Germany.
A common male ancestor illustrates the genealogical relatedness.
2.5. Genome-Wide Association Scan
SNP genotyping was performed using the Illumina Canine HD 174,000 SNP array (Illumina, San Diego,
CA, USA) for 7 affected c ses and 28 neurologically normal adult Saluki cont ols. Genome-wide association
analysis was performed using Plink [20]. SNPs were pruned from analysis if the minor allele f equency
was <5% and the call rate <90%. Chi-square association analysis, Bonferroni adjustments, and genomic
inflation calculations were performed in Plink. Figure 5 was made in R using ggplot2 [21,22].
2.6. Whole-Genome Sequence
Whole-genome sequencing (WGS) was performed on the two affected Salukis from the USA and
compared to 98 controls dogs from various breeds as reported, and coverage was 6.4× for 1052 and
5.3× for 5813 SRA: SRR5311685 and SRR5311664 (study: PRJNA377155) [23]. Segregation of variants
was performed using 2 cases compared to 98 controls within the homozygous interval identified by
visual inspection of genotype calls from the array data. Variant Effect Predictor (VEP), as employed
in Ensembl using Refseq annotation and additional EST/CCDs, was used to predict the effect of
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segregating variants [24]. Polyphen2 [25] and SIFT [26] were used to evaluate the severity of the
missense variants.
In one German Saluki (dog 5), whole-genome sequencing using genomic DNA isolated from the
blood sample of the affected dog was performed as described previously [27]. Data corresponding
to approximately 15× coverage of the genome was collected on an Illumina HiSeq2000 instrument
(2 × 100 bp). Read mapping and variant calling were carried out as previously described [28],
with respect to the CanFam3.1 genome reference assembly and the NCBI annotation release 105.
Variant filtering was performed against 581 dog and 8 wolf genomes which were publicly available [28].
WGS data of the affected dog was made available under study accession PRJEB16012 at the European
Nucleotide Archive (www.ebi.ac.uk/ena; sample accession SAMEA4504825).
Annotations within the canine ALDH5A1 gene refer to the NCBI mRNA accession no. XM_014110599.2
and the protein accession no. XP_013966074.2. Annotations within the GPLD1 gene refer to the NCBI
mRNA accession no. XM_005640079.3 and the protein accession number XP_005640136.1. Annotations for
the putative PTCHD3 gene refer to the mRNA accession no. ENSCAFT00000039442.3 and the protein
accession no. ENSCAFP00000035301.
2.7. Genotyping
The variant in ALDH5A1 disrupted a Sau96I restriction enzyme site, allowing rapid genotyping
by PCR-RFLP analysis. PCR primers were designed using primer 3 [29] to amplify an 872 bp product,
which upon digestion with Sau96I produced 700 and 150 bp fragments for the variant allele and
550 and 150 bp fragments for the wild-type allele. All PCR was carried out using Qiagen HotStart
DNA polymerase kit (Qiagen, Valencia, CA, USA) at an annealing temperature of 58 degrees using
the following PCR primers: F_TCCCGAGTTAGGGGTTCTTT, R_TCACGTTTTCCTGATTTCACC.
The same primers were used to verify the mutation by Sanger sequencing on an Applied Biosystems
3500 Genetic Analyzer using the Big Dye Terminator Sequencing Kit (Life Technologies, Burlington,
ON, Canada).
2.8. RT-PCR
RT-PCR was performed for liver cDNA from a case and control. RPS5 was included as a
housekeeping gene control [27]. Primers were designed using Primer3 (SAL_2F: TTGTATTTGACAGC
GCCAAC, SAL_2R: CAAGGCCAGATTGCTTCAC) except for RPS5, in which the primers were as
recommended [30]. Each reaction included 13.9 µL of water, 2 µL of 10× buffer with MgCl2, 1 µL
of dNTP, 1 µL of each forward and reverse primers (20 µM), 1 µL of HotStarTaq DNA Polymerase
(Qiagen, Valenica, CA, USA), and 1 µL of cDNA made from 1000 ng of RNA. Amplified products were
visualized on a 2% agarose gel.
2.9. Targeted Metabolic Testing
Gamma-hydroxybutyrate (GHB) and succinate semialdehyde (SSA):
GHB and SSA in fluids and brain tissue were quantified by isotope dilution mass spectrometric
methodology, as previously described [31,32].
The 4,5-dihydroxyhexanoic acid (DHHA):
Analysis of DHHA in fluids and brain was comparable to that for GHB as previously described [31],
with some modifications. 2H3-DHHA was used as the internal standard and the samples were extracted
a single time with ethylacetate. For quantitation, positive chemical ionization was employed.
Succinic semialdehyde dehydrogenase (SSADH) activity:
SSADH activity was quantified fluorometrically in brain tissue samples using the NADH/NAD
couple and SSA as substrate, as previously described [33].
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3. Results
3.1. Affected Dogs
Four dogs from two litters from the USA were closely related, and the third litter from Germany
was distantly related to the other two litters. There were four females and three males affected
(Figure 1).
3.2. Clinical Phenotype
The breeders of affected Saluki puppies noted that puppies were first abnormal between six and
ten weeks of age. Historical clinical signs included seizures, abnormal behavior such as episodes of
vocalization (Video S1, Supplementary Materials), and difficulty being aroused from sleep. Four puppies
(dogs 1 and 3–5) were evaluated by a board-certified veterinary neurologist (Table 1). No abnormalities
were noted on physical examination. On neurological examination, puppies had mild generalized ataxia
with thoracic limb hypermetria (two puppies) (Video S2, Supplementary Materials), absent menace
reflex in both eyes and delayed proprioceptive positioning in all four limbs, consistent with a multifocal
disease process. Two dogs (dogs 3 and 4) had a normal CBC and serum biochemical profile completed
by their referring veterinarian, and two dogs had normal quantitative urine organic acid analysis
(Biochemical Genetics Laboratory, University of California San Diego, San Diego, CA, USA). One dog
(dog 5) had a normal cisternal cerebrospinal fluid analysis. Five dogs were treated for seizures with
oral phenobarbital or levetiracetam. Although clinical signs did not progress, all affected dogs were
euthanized as puppies at the request of the breeders when they were still in their care. Puppies were
euthanized between three and nine months of age for quality of life concerns, primarily due to the
recurrent episodes of vocalization. Five dogs (dogs 1–5) had necropsies completed.
3.3. MRI and Histopathology
Two affected dogs (dogs 1 and 2) and four other related but unaffected dogs had an MRI of the
brain. All four unaffected dogs had unremarkable MR images. Both affected dogs exhibited prominent
sulci (Figure 2A,C–E) compared to normal dogs (Figure 2F), consistent with diffuse cortical atrophy.
Bilateral, symmetrical, T2 and FLAIR hyperintensity was present in the diencephalon, deep cerebellar
nuclei (Figure 2A–C), midbrain (Figure 2D), and multiple basal nuclei (Figure 2E). Multifocal, symmetrical
T2 and FLAIR hyperintensity was also present in the deep cortical laminae of the grey matter throughout
the cerebral cortex (Figure 2A–F).
No hypointense lesions or signal voids were observed associated within the brain parenchyma on
T2*W images.
Histopathologically, there was severe bilaterally symmetric spongiform change, worse within
the mesencephalon (Figure 3), brainstem, and deep cerebellar nuclei, but also severe in the thalamic
nuclei and deep cortical grey matter. The corpus striatum was less affected but exhibited similar
lesions most notably in the entopeduncular nuclei and putamen. Neurons exhibited single to multiple,
clear, well-demarcated vacuoles that compressed and displaced the nucleus (Figure 4). There was
marked proliferation of enlarged astrocytes associated with the spongiform change, and both neurons
and astrocytes appear affected. The grey matter was more severely affected, particularly at the
grey–white matter junction. The spinal cord was not affected.
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Table 1. Clinical information for seven SSADHD-affected Saluki dogs. (OU = oculus uterque (both eyes)).
Dog No. Sample ID Country Sex Age of Onset Clinical Signs Neurological Examination Outcome
1 5813 USA F 10 weeks
Generalized epileptic seizures, episodes of
vocalization, abnormal behavior, generalized
ataxia with thoracic limb hypermetria
Mild generalized ataxia with thoracic
limb hypermetria. Delayed
proprioceptive positioning present in all
4 limbs
Treated with anticonvulsants
(phenobarbital), euthanized at 32 weeks
of age
2 4942 USA F 10 weeks
Generalized epileptic seizures, episodes of
vocalization, abnormal behavior, generalized
ataxia with thoracic limb hypermetria
Not done
Treated with anticonvulsants
(phenobarbital), euthanized at 39 weeks
of age
3 1053 USA F 6 weeks
Focal epileptic seizures, episodes of vocalization,
normal between episodes Unable to arouse
when sleeping
Absent menace response OU
Treated with anticonvulsants
(phenobarbital), euthanized at 17 weeks
of age
4 1052 USA M 6 weeks
Generalized and focal epileptic seizures,
episodes of vocalization, normal between
episodes. Unable to arouse when sleeping
Absent menace response OU
Treated with anticonvulsants
(phenobarbital), euthanized at 17 weeks
of age
5 SL006 Germany M 9 weeks Focal epileptic seizures, deep sleep
Thoracic limb hypermetria, mild ataxia,
reduced proprioceptive positioning,
absent menace
Treated with levetiracetam, euthanized at
4 months of age
6 SL008 Germany M 9 weeks Focal epileptic seizures, episodes of vocalization Not done Euthanized at unknown age
7 SL007 Germany F 9 weeks Focal epileptic seizures Not done Euthanized at unknown age
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Figure 2. MRI abnormalities in SSADHD-affected Saluki Dogs. Transverse T2-weighted (A,C–F)
and FLAIR (B) MR images at the level of the cerebellum (A–C), midbrain (D,F) and corpus striatum
(E) demonstrating symmetrical involvement of predominantly grey matter structures. Images from
dog 1 (A,B,D,E), dog 2 (C) and an unaffected littermate (F). Consistent bilateral symmetrical T2
hyperintensity of the deep cerebellar nuclei ((A–C); white arrowheads) is the most prominent finding.
Similar bilaterally symmetrical hyperintensity is seen involving the tectum and dorsal tegmentum ((D);
black arrowhead) and endopeduncular (medial) and lentiform nuclei ((E); white arrowheads) but not
present in unaffected dog images (F). Sulci are prominent (D) compared to an unaffected age matched
control (F), consistent with atrophy of cortical grey matter. Hyperintensity of deep cortical grey mater
laminae is evident on T2-weighted and FLAIR images at all levels (white arrows) is not present on
unaffected dog MR images (F).
3.4. Genetic Analysis
Both sexes are affected and in-depth pedigree analysis revealed the presence of a common male
ancestor connecting the American and European families (Figure 1). As all parents of affected offspring
show no clinical signs, it could be speculated that the observed disease phenotype follows autosomal
monogenic recessive inheritance. Genome-wide association was performed using DNA samples from
the seven affected dogs (Figure 1) and 28 phenotypically normal Saluki controls. After quality control,
there were 108579 SNPs available for association. A single genome-wide significant association signal
based on a pBonferroni (0.006) on CFA 35 (chr35: g23,654,869; praw 5.27 × 10−8) was identified (Figure 5).
Furthermore, a 2.683 Mb region of homozygosity was identified in the seven affected dogs on CFA 35:
21,925,974–24,608,949 bp (CanFam3.1).
In order to identify a causative variant, initially paired-end whole-genome sequences of 2 affected
puppies from two American litters (1052, 5813: Figure 1) and 98 unaffected controls from various
breeds were investigated in the associated interval. There were 35,982 single-nucleotide variants
(SNVs) and 16,832 insertion/deletion (indel) variants identified within the critical interval defined by
homozygosity: CFA 35: 21,925,974–24,608,949 bp (CanFam3.1). There were 259 SNVs and 41 indels
that segregated with the phenotype in the 100 animals. There were three coding variants identified:
a synonymous variant (g.22,506,956G>A) in the GPLD1 gene, and two protein-changing missense
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variants, g.22,572,768G>A in the ALDH5A1 gene, and g.23,908,560T>C in the putative PTCHD3 gene.
The synonymous variant in GPLD1 was not investigated further.
The two missense variants in ALDH5A1 (XM_014110599.2: c.866G>A; XP_013966074.2: p.(Gly288Asp))
and PTCHD3 (ENSCAFT00000039442.3: c.1247T>C; ENSCAFP00000035301: p.(Iso416Thr)) were
evaluated to identify whether the substitutions were potentially deleterious. There is a gap in the
canine genome assembly that likely contains at least one additional exon of the ALDH5A1 gene.
Aligning the predicted canine ALDH5A1 protein sequence with the human protein sequence places
the canine missense variant at amino acid 381 in human (NP_001071.1). Both PolyPhen2 [25] (probably
damaging—1.0) and SIFT [26] (deleterious—0.0) predicted this amino acid substitution to be deleterious.
It occurs in a well -conserved portion of the protein (Figure 6B). The missense variant in PTCHD3 is not
predicted to affect the protein based on PolyPhen2 [25] (benign-0.436) and SIFT [26] (tolerated-0.05).
In addition, based on the known functions of these two proteins and the independent findings presented
below, the ALDH5A1 variant was the only one pursued further.Genes 2020, 11, x FOR PEER REVIEW 9 of 22 
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Figure 3. Histopathology of mesencephalon and brainstem from dog 1. (A) Bilaterally, the mesencephalic
nuclei of cranial nerve V (*), the red nuclei (**), and the substantia nigra (***) exhibit decreased staining
intensity (H&E). (B) Bilaterally, the deep cerebellar nuclei (*), the dorsal nuclei of the trapezoid body (**),
and the reticular formations (***) exhibit decreased staining intensity (H&E). (C) Higher magnification of
(A), inset. The substantia nigra shows prominent vacuolation of affected neurons. (D) Higher magnification
of (B), inset. The interposital nucleus shows reactive astrocytes (arrow), some of which also contain
prominent cytoplasmic vacuolation (arrowhead).
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deep cortical nature of the vacuolation (E) within the cerebrum. (F) Vacuolation is discrete and often displaces cellular nuclei LFB staining.
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No private variants were found in the GPLD1 and PTCHD3 genes. Furthermore, only one protein-
changing missense variant (ALDH5A1: XM_014110599.2: c.866G>A) remained after filtering for 
Figure 5. GWAS for SSADHD-affected Saluki dogs. (a) Manhattan plot showing –log10 of the raw
p-values for each genotyped SNP by chromosome (x-axis). Genomic inflation was 1.25. Line denotes
genome-wide significance based on Bonferroni-corrected p-values. (b) Q–Q plot of samples used in
GWAS showing the −log10 of the expected versus the observed p-values. The SNPs on CFA35 are
shown in light grey.
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Figure 6. SSADHD-associated ALDH5A1 missense variant in Saluki dogs. (A) The electropherograms
from a normal dog (top panel), a heterozygous dog (middle panel) and a dog homozygous for the
variant in ALDH5A1 indicated by an ar w. (B) The amino acid alignment round the missense variant
in ALDH5 1 (XP_0 3966074.2: p.(Gly288Asp)). Yellow boxes indic te 100% conservation acro s th
species listed to the left and blue boxes indicate 75% conservati n. The variant amino a id r sidue is
boxed and th variant allele d t c ed in affected Salukis is shown in red. (C) The PCR-RFLP genotyping
assay for the ALDH5A1 missense variant is show . After PCR ampl fication, the products were digested
with Sau96I. L is the DN ladder, WT tands for wild type (542 bp), for carrier and M for mutant
(702 bp).
Independently, the ge ome of an affected puppy (dog 5) from the Ger a litter was sequenced.
No private variants were found in the GPLD1 and PTCHD3 genes. Furthermore, only one protein-
changing missense variant (ALDH5A1: XM_014110599.2: c.866G>A) remained after filtering for
homozygous private variants in the region of interest on chromosome 35 against the 589 control
genomes from the Dog Biomedical Variant Database Consortium (DBVDC) variant catalog [27].
The ALDH5A1 variant was confirmed by Sanger sequencing of genomic DNA (Figure 6A). In order
to genotype the ALDH5A1 missense variant, a PCR-RFLP genotyping assay was used (Figure 6C).
Genotyping of the ALDH5A1 missense varia t was performed in the seven affected dogs used for
the GWAS, and the four available parents (Figure 1). The variant was homozygous in all cases and
heterozygous in the parents. Siblings and other relatives, as well as unrelated Saluki dogs, were genotyped;
13 were heterozygous carriers and 48 were homozygous wild type. The segregation of the ALDH5A
variant fits perfectly with the assumed monoge ic recessive Mendelian inheritance within the studied
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family. In-depth pedigree analysis revealed the presence of a common male ancestor connecting the
American and European families (Figure 1). To experimentally determine whether the ALDH5A variant
was a common canine variant, 228 dogs from various other breeds were genotyped and all were found
to have the wild-type allele, which was also confirmed by the absence of the variant in 581 dogs from
125 breeds and eight wolves of the DBVDC cohort [27].
The presence of the variant in cDNA of an affected dog was verified by Sanger sequencing of
RT-PCR product from liver of an affected Saluki compared to a control unaffected dog. There was no
obvious difference in expression level between the case and the control. Quantitative evaluation was
not possible since only one affected dog sample was available. Our results have been integrated in the
Online Mendelian Inheritance in Animals (OMIA) database (https://omia.org/OMIA002250/9615/).
3.5. Targeted Metabolic Testing
Targeted quantitative organic acids were analyzed on urine, serum, CSF, and brain tissue (Table 2)
in affected (n = 1 to 4) and control dogs (n = 2 to 4). Compared to control dogs, there were marked
elevations in urine succinate semialdehyde (SSA) and urine 4,5-dihydroxyhexanoic acid (DHHA) but
levels of gamma hydroxybutyrate (GHB) in the urine were normal. Serum GHB and serum DHHA
from affected dogs were markedly elevated compared to controls. Serum SSA could not be measured in
either affected or control dogs. In cisternal cerebrospinal fluid (CSF) and brain, SSA, GHB and DHHA
were markedly elevated in the affected dog compared to controls, with the CSF GHB having the highest
elevation (by a factor of at least 4800). Activity of succinate semialdehyde dehydrogenase (SSADH)
was absent or markedly reduced to 0.18% of normal in the affected dogs compared to control dogs.
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Table 2. Specific quantitative organic acids in urine, serum, CSF, and brain tissue in affected and control dogs (nd = not done).
Dog Number
Urine SSA,
mmol/mol
Creatinine
Urine GHB,
mmol/mol
Creatinine
Urine DHHA
mmol/mol
Creatinine
Serum
GHB,
µmol/L
Serum
DHHA,
µmol/L
CSF SSA,
µmol/L
CSF GHB,
µmol/L
CSF
DHHA,
µmol/L
Brain GHB,
nmol/mg
Brain
Brain DHHA,
nmol/mg
Brain
Brain SSA,
nmol/mg
Brain
Brain SSA
Activity,
pmol/min/mg
Protein
1 9.23 1.06 5.85 6.59 0.45 69 >1500 43.3 2.43 0.22 0.23 10
2 nd nd nd nd nd nd nd nd 2.93 0.28 0.18 0
5 38.7 nd 11.8 nd 0.41 nd nd nd nd nd nd nd
6 30.9 0.67 10.4 nd 0.61 nd nd nd nd nd nd nd
7 nd nd nd nd 0.56 nd nd nd nd nd nd nd
Number of affected dogs 3 2 3 1 4 1 1 1 2 nd 2 2
Number of control dogs 4 4 4 4 4 2 3 3 4 nd nd 4
median affected 30.9 0.87 10.4 n/a 0.51 n/a n/a n/a 2.68 0.25 0.21 5
range affected 9.23–38.7 0.67–1.06 5.85–11.8 n/a 0.41–0.61 n/a n/a n/a 2.43–2.93 0.22–0.28 0.18–0.23 0–10
median control 0.86 0.82 0.29 0.38 0.08 0.24 0.31 0.11 0.03 0 0.11 5587
range control 0.64–0.9 0.29–2.04 0.18–0.65 0.28–0.59 0.07–0.1 0.02–0.46 0.23–0.8 0.1–0.2 0–0.05 0–0 0.06–0.14 4214–5942
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4. Discussion
A pathogenic variant in the canine ALDH5A1 gene associated with recessive SSADH deficiency,
formerly known as status spongiosus in Saluki dogs (SSSD) [13]. Seven Saluki puppies from two
continents had an onset of multifocal cranial neurological signs at 10 weeks of age or younger.
Blood work was normal. On MRI of the brain, lesions were similar in all dogs, with bilateral and
symmetrical lesions of the cerebrum, brainstem and cerebellum, predominantly affecting grey matter
structures. Because this disorder occurred in purebred Saluki puppies from different environments
with a consistent clinical phenotype and a normal extracranial work up, structural epilepsy from an
inborn error of metabolism was considered the most likely etiology. Using genome-wide association,
followed by whole-genome sequencing, a missense mutation in the ALDH5A1 gene was identified as
the presumed cause of status spongiosus in Saluki dogs, previously reported in Saluki puppies [13].
The mutation segregated completely in family members as an apparently fully penetrant monogenic
recessive disorder.
The ALDH5A1 gene encodes the mitochondrial enzyme succinic semialdehyde dehydrogenase
(NAD+) (SSADH), which is involved in the catabolism of the inhibitory neurotransmitter gamma-
aminobutyric acid (GABA) (Figure 7). GABA is the major inhibitory neurotransmitter in the central
nervous system(CNS), where it is utilized in up to 30% of cerebral synapses [34]; it is also found in
non-nervous-system tissue. GABA is synthesized from L-glutamate via glutamate decarboxylase
(GAD). The first step in GABA metabolism is by GABA-transaminase (GABA-T) to form succinic
semialdehyde (SSA). SSA is then oxidized by the mitochondrial protein succinic semialdehyde
dehydrogenase (NAD+) (SSADH) to succinic acid, which then enters the tricarboxylic acid (TCA)
cycle for energy generation (Figure 7). In people, recognized disorders of GABA synthesis are GAD
deficiency, and recognized disorders of GABA degradation are GABA transaminase deficiency and
succinic semialdehyde dehydrogenase (NAD+) (SSADH) deficiency.
The SSADH protein is expressed in the mammalian brain, as well as liver, pituitary, heart, ovary
and kidney [35]. In people, the ALDH5A1 gene is located on chromosome 6p22, and is 10 exons
long extending over 38 kb [36]. Succinic semialdehyde dehydrogenase (NAD+) is an enzyme which
is member of the aldehyde dehydrogenase family of proteins. In people with SSADH enzyme
deficiency, SSA is not catabolized to succinic acid, and thus excess levels of SSA build up in tissues
and fluids (Figure 7). Excess succinic semialdehyde is converted to 4-hydroxybutyric acid (GHB) by
succinic semialdehyde reductase. Excess SSA may also interact with an intermediate in the pyruvate
dehydrogenase complex to form 4,5-dihydroxyhexanoic acid (DHHA). People with a deficiency of
SSADH have elevations of SSA, DHHA, and GHB in body fluids [35]. The activity of SSADH is reduced
in people, and thus levels of SSA rise, with associated high levels of GHB and DHHA (Figure 7) [37].
The hallmark of SSADH deficiency in people is persistent and elevated levels of the GHB in urine,
plasma and CSF [37]. The diagnosis is confirmed by molecular genetics by sequencing the ALDH5A1
gene for pathogenic variants. There is no effective therapy [37].
In Saluki dogs with SSADH deficiency, levels of SSA and DHHA are elevated in urine, serum,
CSF and brain, and GHB is elevated in serum, CSF and brain. Unlike in people, where GHB is elevated
in urine, the level of GHB in urine in Saluki dogs with SSADH deficiency is normal. Since the activity of
succinate semialdehyde dehydrogenase (NAD+) (SSADH) was absent or markedly reduced, along with
elevated levels of SSA, DHHA and GHB, we believe that the previously described central nervous
system status spongiosus in Saluki dogs should be more appropriately termed succinic semialdehyde
dehydrogenase deficiency (SSADHD).
In people, SSADH deficiency is a rare autosomal recessive neurological disorder caused by a
mutation in the ALDH5A1 gene, reported in 1981 (OMIM 271980) [38]. There are 44 unique mutations in
the ALDH5A1 gene, which occur in exons 1–10; there are no other mutations in genes other than ALDH5A1
associated with SSADH deficiency in people [36]. The clinical features in people include developmental
delay, hypotonia, intellectual disability, ataxia, seizures, hyperkinetic behavior, aggression and sleep
disturbances. Approximately 50% of patients have seizures, 45% have neuropsychiatric problems such
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as sleep disturbances, and many patients also have behavioral abnormalities [34], which all worsen with
age [39]. The encephalopathy is considered non-progressive and has wide phenotypic heterogeneity
from mild to severe. Symptoms are first noted at a mean of 11 months (range 0–44 months of age),
with a mean age at diagnosis of 6.6 years (range of 0 to 25 years) [40]. On MR imaging in people with
SSADHD, MR images may be normal, or there may be hyperintensities on T2-weighted imaging in the
globus pallidus, cerebellar dentate nuclei and brainstem [41]. A small percentage of people are reported
with cerebral white matter hyperintensity on MR imaging as well [41]. There is one single case report
of the pathology of SSADH deficiency in a young adult, where there was discoloration of the globus
pallidi, congestion of the leptomeninges and scar tissue in the cerebral cortex [42].Genes 2020, 11, x FOR PEER REVIEW 16 of 22 
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and scar tissue in the cerebral cortex [42]. 
The pathophysiology of SSADH deficiency in people is complex. The disease is thought to be 
caused primarily by the elevation of GHB in the brain, particularly during neurodevelopment or due 
to the imbalance of neurotransmitters [43] but also potentially from oxidative stress in the brain [44]. 
GHB is a neuromodulator with a wide array of pharmacological effects [45]. It was initially produced 
Figure 7. GABA catabolism pathway. In Saluki dogs with SSADH deficiency, levels of SSA and DHHA
are elevated in urine, serum, CSF and brain, and GHB is elevated in serum, CSF and brain (red arrows)
as in people with SSADH deficiency. Unlike in people, where GHB is elevated in urine (red arrow),
the level of GHB in urine (red *) in Saluki dogs with SSADH deficiency is normal.
The pathophysiology of SSADH deficiency in people is complex. The disease is thought to
be caused primarily by the elevation of GHB in the brain, particularly during neurodevelopment
or due to the imbalance of neurotransmitters [43] but also potentially from oxidative stress in the
brain [44]. GHB is a neuromodulator with a wide array of pharmacological effects [45]. It was initially
produced as an injectable anesthetic agent but is now longer utilized for this purpose due to adverse
effects but is prescribed to treat cataplexy in narcolepsy/cataplexy, opiate dependency and alcoholism,
and is a drug of abuse, where its street names include Grievous Bodily Harm, Liquid Ecstasy and
Soap [46]. GHB may cause anxiolytic, hypnotic and euphoric effects as well as short-term memory loss
and CNS depression, causing sedation [44,47]; intoxication may cause bradycardia, myoclonus and
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seizures, hypoventilation, coma and death from respiratory depression [33]. GHB is a monocarboxylate
that is primarily cleared from the plasma via metabolism in a dose-dependent fashion through the
Kreb’s cycle. Renal clearance of GHB is minor and non-linear, due to the carrier-mediated saturable
renal reabsorption of GHB through the proximal tubules via sodium-dependent and pH-dependent
monocarboxylate transporters. Methods to increase the renal excretion of GHB have been investigated
in animals as part of a treatment plan for people with GHB intoxication, such as with the intravenous
administration of L-Lactate which increases the renal excretion of GHB [48,49].
As there are no effective specific treatments for SSADH deficiency in people, treatment is
currently aimed at managing the clinical signs of seizures and neurobehavioral disturbances [34].
Broad-spectrum anticonvulsants are generally utilized, avoiding valproate which inhibits SSADH
which may worsen GHB accumulation and clinical signs [50]. However, there are many therapeutic
options under investigation which include pharmacological (e.g., targeting neurotransmitter receptors),
enzyme-replacement therapy, gene therapy and treatment with pharmacological chaperones [51,52].
In animals, SSADH has been produced in knockout mice; clinical signs are progressive ataxia,
failure to thrive, seizure and death at a young age [53,54], and thus they are utilized as a model
for the severe and poor survival phenotype in humans. There are no reports of the MR imaging
features of SSADH-knockout mice [51] and, on pathology, there are no reported abnormalities on
routine hematoxylin and eosin staining, but detailed neuropathological examinations have not been
performed [55]. There is a single case report of a dog with suspected SSADH deficiency, which had a
progressive encephalopathy with profound and persistent lactic acidosis, elevated urine GHB and
a 30% reduced activity of SSADH measured in cultured lymphoblasts compared to normal dogs.
Intracranial MR imaging of the brain was not performed; on histopathology of the brain, there was a
spongiform change in the cerebral cortex [56].
Saluki dogs have a more severe phenotype of SSADHD than people, but with very similar
clinical signs of seizures, abnormal behavior, abnormalities of sleep and multifocal brain disease
on neurological examination. Like people [42], affected Salukis have multifocal abnormalities in
the brain on MR imaging, where affected dogs have identical bilaterally symmetrical T2-weighted
hyperintensities in the same anatomical areas as people such as the basal nuclei, deep cerebellar
nuclei, and brain stem. In people with SSADH deficiency, these abnormalities have considerable
consistency, and are almost universal. However, in some people, there are reports of non-specific
hyperintensities in subcortical white matter and the substantia nigra in the brainstem, as well as
cerebellar atrophy [57,58]. These abnormalities are not considered specific for SSADHD, but considered
to be imaging characteristics of cytotoxic edema, secondary to oxidative stress from the underlying
SSADHD [43]. Differently to what is noted in people, dogs have hyperintensity of the deep cortical
laminae of the grey matter of the cerebral cortex and atrophy of the cerebral cortex. On histopathology
in dogs with SSADH deficiency, there is bilaterally symmetric multifocal spongiform change in the
brainstem, deep cerebellar nuclei, but also severe in the thalamic nuclei and deep cortical grey matter.
The brain lesions in affected Salukis on MRI (two dogs) and pathology (three dogs (same two dogs that
had MRI plus one other) were identical. There is only one case report of the pathology of SSADHD in
a person where the histopathology was not described and thus the comparative pathology between
dogs and people is not possible [42].
Unlike in people with SSADHD, where GHB is elevated in the urine and therefore is an excellent
biomarker, GHB is not elevated in the urine of affected dogs. GHB is, however, elevated in the serum,
CSF and brain tissue of affected dogs. Since GHB is extensively reabsorbed from the proximal tubules in
the kidney [59], it is possible that species differences in handling GHB resulted in extensive reabsorption
of GHB and in a normal level of GHB in the affected dog’s urine. It is also plausible that since urine
GHB was evaluated in only two affected dogs, that evaluation of additional SSADHD-affected dogs
may have yielded elevated levels of urine GHB. There may also have been loss of GHB in the samples
during shipping to the lab or storage, as GHB is a volatile compound [40] and a reduction in GHB
levels is reported with storage, which varied between 10% loss at just 3 days and in excess of 20% after
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4 weeks of storage [60]. If the activity of the D-2-hydroxyglutarate dehydrogenase in liver (non-cofactor
enzyme converting GHB to SSA and ketoglutarate to D-2-hydroxyglutarate) was very active in the
liver of Salukis, this could be a plausible explanation for why GHB was not elevated in the urine;
however, D-2-HG was not measured in affected or control dogs. Otherwise, aside from serum SSA that
we were not able to measure in dogs with SSADHD, dogs are similar to human patients in regards to
elevated body fluid levels of SSA, DHHA and GHB, and zero to low levels of brain SSA activity.
5. Conclusions
Saluki dogs with SSADHD have a disease phenotype resembling SSADHD in people, although it
appears to be more severe clinically. On the other hand, it appears to be less severe than the phenotype
described in in knockout mice, which is lethal [58]. Furthermore, GHB may not be an acceptable
biomarker for the disease in dogs; alternatively, urine SSA or GHB in serum may be more appropriate
biomarkers. Compared to mice models of human disease, dog models have naturally occurring disease,
are more similar to humans in regards to size, and have more longevity than mice. Dogs are proven and
valuable models of human disease, particularly in the field of lysosomal storage diseases [6]. This first
ALDH5A1-related large animal model for SSADHD may provide an opportunity for evaluation of
potential therapeutics for this rare orphan disease in people. Dogs may be a more appropriate disease
model than the murine SSADH model, as dogs appear to have a more similar disease phenotype and
similar MR imaging features to people. The identification of the pathogenic ALDH5A1 variant will
allow the screening of carriers to avoid producing further affected puppies and thereby contribute to
maintaining breed health.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/9/1033/s1.
Video S1: A Saluki puppy (dog number 5) showing an episode of abnormal vocalization, Video S2: A Saluki
puppy (dog number 1) with bilateral thoracic limb hypermetria.
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